Survodutide Survodutide, developed jointly by Boehringer Ingelheim and Zealand Pharma, is an investigational long-acting, GCGR/GLP-1R agonist targeting obesity by increasing energy expenditure and reducing food intake and MASH
Additionally, all included studies were RCTs, thereby reducing within-trial bias
This approach aligns with the growing trend of consumer-driven health management, driven by increased access to medical information and the expansion of telemedicine, Isman explains
Armando Valenzuela-Peraza, orcid.org/0000-0002-9293-186X
Earlier research has tied CADM2 to traits such as impulsivity, obesity, and cancer metastasis
95% CI 0.05 0.19) and IL-6 (ES 0.20